Showing results (341-350 of 482) with videos related to

Sort By:
Pageof 49
Cardiovascular Diabetology|November 5, 2024
Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary interventionEun Ho Choo, Donggyu Moon, Ik Jun Choi, et al.
Plos One|January 25, 2018
Comparisons of oncological outcomes and perioperative complications between laparoscopic and open radical nephrectomies in patients with clinical T2 renal cell carcinoma (≥7cm)Hakmin Lee, Chung Un Lee, Jae Ho Yoo, et al.
Plos One|June 8, 2022
Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen valueJae Hoon Chung, Jae Yong Jeong, Ji Youl Lee, et al.
Urologic Oncology|November 4, 2008
Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapyHyo Song Kim, Won Seog Kim, Se Hoon Park, et al.
Cancers|September 9, 2022
Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 LesionsChung-Un Lee, Sang-Min Lee, Jae-Hoon Chung, et al.
International Heart Journal|November 14, 2007
Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunctionDong Il Shin, Pum Joon Kim, Ki-Bae Seung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2014
Suggestion for the prostatic fossa clinical target volume in adjuvant or salvage radiotherapy after a radical prostatectomyJun Su Park, Won Park, Hong Ryull Pyo, et al.
Korean Journal of Urology|March 1, 2014
High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after radiotherapyWan Song, U Seok Jung, Yoon Seok Suh, et al.
Urology|March 23, 2010
Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mLHong Seok Kim, Seong Soo Jeon, Jae Duck Choi, et al.
Cancer Management and Research|September 2, 2024
Prognostic Role of Pre-Treatment Body Composition Parameters in Patients Undergoing First-Line Immunotherapy for Metastatic Renal Cell CarcinomaSangmin Lee, Jae-Hun Kim, Wan Song, et al.
Pageof 49